Cancers & treatments·Regimen libraryFirst line

Gemcitabine + nab-paclitaxel

Checked 2026-09-09

Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated

One cycle

every 28 days

28-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
nab-Paclitaxel Cytotoxic chemotherapy (taxane)	125 mg/m²	IV	D1, 8, 15
Gemcitabine Nucleoside analogue (deoxycytidine)	1,000 mg/m²	IV	D1, 8, 15

Cycles

until progression

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Used in

Pancreatic ductal adenocarcinoma

Products

Gemcitabine + nab-paclitaxelPaclitaxel / nab-paclitaxelGemcitabine

Source

MPACT, NEJM 2013

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.